




Myles McNulty
9.4K posts

@MylesMcNulty
Former micro-cap equity analyst, former micro-cap-focussed investment manager. Now managing my own book, predominantly trading UK micro-caps.






CHINA'S RARE EARTH MAGNET EXPORTS TO JAPAN REMAIN LOW IN JUNE – NIKKEI

#AGI This is Potentially a frontier AI play that's going to become a champion for what the UK can do. Solving a problem nobody else has. open.substack.com/pub/thatstocks…





Trump is literally spelling out to us what to invest in next: Rare earth magnet plants, on US soil. $MKA #MKA and JV partner $CTH are building out at least three HyProMag magnet recycling and remanufacturing plants in the US (and possibly as many as seven), which will likely be the lowest cost magnet manufacturing facilities in the world (certainly, outside of China). For Mkango in particular (which owns c.80% of HyProMag), the current valuation is just nonsensical. Its upstream (non-magnet!) business is listing on NASDAQ in the next couple of months at 77.5p per share equivalent (versus MKA's current SP of 39p) - meaning that HyProMag is priced at less than zero, in MKA's mkt cap.



Trump: "Magnets! Do magnets, okay? I'll tell you how to make money. Do magnets. It's one thing we don't have, but we're getting close. I guarantee you it's gonna be susssessullll"



Avacta is a small British biotech most of FinTwit couldn't name. AIM-listed. Spent the last two years selling off its diagnostics business - Launch Diagnostics went to Palex for £12.9m in 2025 - to go all-in as a pure-play oncology company. 1 June: ASCO data showed no severe cardiac toxicity on its lead cancer drug. Three weeks later, the FDA agreed it can skip straight to ONE pivotal trial for full approval - progression-free survival as the sole endpoint. Salivary gland cancer is a small indication though. Whether this becomes a platform story or stays a one-drug story depends on what the next readout shows. $AVCT






Fibroblast activation protein (FAP) is expressed by cancer-associated fibroblasts (CAFs) within the tumor stroma. CAFs may: ➡️Drive tumor progression ➡️Promote therapy resistance ➡️Enable targeted ionizing radiation delivery to tumor cells 🔗e.lilly/49m2JgN #Theranostics






Great perspective of Sethera Therapeutics CEO @ BIO San Diego. BP want differentiated science but they're careful that it can be developed, manufactured, protected and advanced. In that environment peptide therapeutics are becoming more attractive #AVCT biospectrumasia.com/influencers/25…